Mimedx (MDXG) Cash from Discontinued Operations (2023 - 2024)
Mimedx (MDXG) reported Cash from Discontinued Operations of 1000.0 for Q4 2024, down 99.9% on a YoY basis from 987000.0 in Q1 2024, and up 200.0% sequentially from 1000.0 in Q3 2024.
Mimedx (MDXG) Cash from Discontinued Operations (2023 - 2024) Analysis & Trends
Mimedx (MDXG) has 2 years of Cash from Discontinued Operations data on file, last reported at 1000.0 in Q4 2024.
- For the quarter ending Q4 2024, Cash from Discontinued Operations fell 99.9% year-over-year to 1000.0; the trailing twelve-month figure through Sep 2025 stood at 1000.0 (down 98.21% YoY), and the FY2024 full-year result was 930000.0, up 88.61% from the prior year.
- Cash from Discontinued Operations rose to 1000.0 in Q4 2024, from 1000.0 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of 987000.0 in Q4 2023 to a low of 4648000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | - |
| 10 | Mimedx | 639.80 Mn | 480.03 Mn | 41.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -123,000.00 |
| Jun 30, 2024 | -123,000.00 |
| Mar 31, 2024 | -807,000.00 |
| Mar 31, 2024 | -807,000.00 |
| Dec 31, 2023 | 987,000.00 |
| Dec 31, 2023 | 987,000.00 |
| Sep 30, 2023 | -309,000.00 |
| Sep 30, 2023 | -309,000.00 |
| Jun 30, 2023 | -4.19 Mn |
| Jun 30, 2023 | -4.19 Mn |
| Mar 31, 2023 | -4.65 Mn |
| Mar 31, 2023 | -4.65 Mn |